JD Bioscience focuses on the discovery and development of novel therapeutics aimed at addressing metabolic diseases that currently lack effective treatments. The company employs a target-based drug discovery process, which includes identifying unmet medical needs, searching for new drug targets, and utilizing advanced techniques such as fragment-based drug design and AI-based hit identification. Their research pipeline includes various conditions such as Non-Alcoholic Steatohepatitis (NASH), Inflammatory Bowel Disease (IBD), heart disease, pancreatitis, cancer, and fibrosis, indicating a broad commitment to tackling significant health challenges.

The company emphasizes a systematic approach to drug development, which involves lead identification and optimization, as well as the synthesis of proprietary chemical compounds. JD Bioscience also focuses on discovering novel biomarkers and evaluating patient samples to enhance their understanding of specific diseases. This comprehensive methodology not only aims to create effective treatments but also seeks to improve the overall quality of life for patients suffering from metabolic disorders.

South Korea

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases.

Cancer

Digestive System Diseases

Immune System Diseases

Infectious Diseases

Pathological Conditions

JD Bioscience

Fibrosis

Non-alcoholic steatohepatitis

GM-60106

Small Molecule Pharmaceuticals

Inflammatory disease

GM-10395

Pancreatitis

Sepsis

GM-10134

GM-60387

Artificial Intelligence

Therapeutic

JD Bioscience

Company Details